AUAUniversity

Kidney Cancer & SBRT in the Management of RCC

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Daniel Shapiro, MD

Outline:

Segment 1: History of radiation therapy in renal cell carcinoma

Segment 2: Radiation use in the setting of primary kidney tumors

Segment 3: Radiation use for locally advanced tumors including tumor thrombi

Segment 4: Radiation therapy for metastatic disease

Segment 5: Limitations of radiation therapy and selecting patients for radiation therapy

Pediatric Urology: Differences of Sex Development

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Emilie Johnson, MD, MPH, FACS, FAAP

Outline:

Segment 1: DSD Nomenclature – Words Matter!

Segment 2: Multidisciplinary Care Model

Segment 3: Example Conditions

Segment 4: Approach to Prenatal and Early Postnatal Care

Segment 5: Gonadal Management – also evolving

How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent

CME Available: https://auau.auanet.org/node/41124

At the conclusion of this activity, participants will be able to:

1. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.

2. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.

3. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.

4. Identify patients with radiorecurrent organ-confined prostate cancer.

5. Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

The Changing Face of Advanced Prostate Cancer 2024

CME Available: https://auau.auanet.org/node/41136

At the conclusion of this activity, participants will be able to:

1. Identify and treat a patient with newly diagnosed M1 prostate cancer with androgen deprivation therapy plus be able to offer novel ADT. Furthermore, recognize high-volume new M1 prostate cancer so as to be able to refer to a genitourinary medical oncologist for chemotherapy if necessary.

2. Diagnose M0 CRPC, and be able to educate patients about using novel oral androgen receptor inhibitors added to traditional androgen deprivation therapy as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, understand the differences between these novel oral agents and educate patients about side effects and toxicities. Finally, understand the role or lack of role of prostate-specific membrane antigen PET in working up this disease state.

3. Apply the latest phase III randomized controlled trial results for new therapies in M1 CRPC, and be able to educate their patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer.

4. Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape, and for providers and teams to embrace the multidisciplinary nature of care for our patients.

5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents and novel androgen receptor-targeted agents emerging in 2024.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

Prostate Cancer Diagnosis: AUA Guidelines on use of PSA Biomarkers, MRI and Biopsy Techniques

CME Available: https://auau.auanet.org/node/41113

At the conclusion of this activity, participants will be able to:

1. Apply the Early Detection of Prostate Cancer: AUA/SUO Guideline (2023), and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement.

2. Identify how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically significant prostate cancer, while avoiding unnecessary biopsies and detection of clinically insignificant prostate cancers.

3. Identify the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences.

4. Identify available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use, and the clinical scenarios in which they are most valuable to be used.

5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer and implement safe biopsy practices with respect to approach, avoidance of infection, and attention to patient comfort; understand the rationale for transperineal prostate biopsy and its technique; be able to establish a transperineal biopsy practice.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice

CME Available: https://auau.auanet.org/node/41033

At the conclusion of this activity, participants will be able to:

1. Identify the research that led to the approval of genomic cancer for prostate cancer and the implementation of advanced imaging for prostate cancer.

2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation.

3. State the National Comprehensive Cancer Network Guidelines for genomic testing and advanced imaging for prostate cancer.

4. Discern the different prognostic end points provided by various genomic tests.

5. Recognize candidates for, and implications of, germline testing for prostate cancer.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2024: Upper Tract Urothelial Cancer (UTUC) Guidelines

Upper Tract Urothelial Cancer (UTUC) Guidelines – An Interactive and Evidence-Based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video Presentation

CME Available: https://auau.auanet.org/node/41021

At the conclusion of this activity, participants will be able to:

1. Identify demographics, predisposing risks, hereditary factors, common terms.

2. Describe workup, imaging, role of standardized endoscopic assessment, cytology and biopsy.

3. Apply clinical features of disease risk, role of risk assessment and management options.

4. Identify candidates for endo management, describe counseling/risks, safe approaches, troubleshooting.

5. Explain setting and role for adjunctive chemotherapy use, importance of renal function, genetic counseling; describe approach to ureterectomy/bladder cuff, node dissection templates, intravesical therapy use; explain the rationale and use of risk-adjusted follow-up for endoscopy and imaging.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Merck & Co., Inc.

The Surgical Management of BPH and Updates from the AUA Clinical Guidelines Podcast (2024)

CME Available: https://auau.auanet.org/node/41595

ACKNOWLEDGEMENT:

This educational series is supported by an independent educational grant from Olympus Corporation of the Americas.

At the conclusion of this activity, participants will be able to:  

1. Describe the role of the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.

2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.

3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.

4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.

New AUA Guideline (2024): Salvage Therapy for Prostate Cancer

CME Available: https://auau.auanet.org/node/41074

At the conclusion of this activity, participants will be able to:

1. Identify and effectively interpret the optimal timing of salvage radiation therapy following radical prostatectomy, considering the factors that can influence this decision in a clinical context.

2. Develop an understanding of which patients should receive ADT alongside salvage radiation therapy following radical prostatectomy, and how to appropriately decide the duration of ADT for patients.

3. Identify and analyze the use of risk stratification tools and next-generation imaging techniques for guiding treatment decisions and monitoring in patients with biochemical recurrence following primary therapy.

4. Evaluate the role and benefits of advanced treatment options such as intensified systemic therapy and metastasis-directed therapy.

5. Evaluate and understand the indications, efficacy, and potential complications of different salvage local therapies, such as salvage prostatectomy, radiotherapy and cryotherapy, for patients with local recurrence following primary radiation therapy.